

THYMOQUINONE AND ITS NANO-FORMULATIONS FOR DRUG DELIVERY

SURBHI GOEL



DEPARTMENT OF BIOCHEMICAL ENGINEERING AND BIOTECHNOLOGY

INDIAN INSTITUTE OF TECHNOLOGY DELHI

JULY 2018

©Indian Institute of Technology Delhi (IITD), New Delhi, 2018

**THYMOQUINONE AND ITS NANO-FORMULATIONS FOR
DRUG DELIVERY**

by

SURBHI GOEL

Department of Biochemical Engineering and Biotechnology

Submitted

in fulfilment of the requirements of the degree of Doctor of Philosophy

to the



INDIAN INSTITUTE OF TECHNOLOGY DELHI

JULY 2018

DEDICATED

TO

MY FATHER AND MY

HUSBAND

CERTIFICATE

This is to certify that the thesis entitled “**Thymoquinone and its nano-formulations for drug delivery**” being submitted by **Ms. Surbhi Goel** is worthy of consideration for the award of the degree of **Doctor of Philosophy**. The thesis has been prepared by her under my supervision and guidance in conformity with the rules and regulations of Indian Institute of Technology Delhi and is a record of the original bonafide research work. The results presented in this thesis have not been submitted in part or full to any other universities or institutes for the award of any other degree or diploma.

Prashant Mishra, Ph.D

Professor

Department of Biochemical Engineering

& Biotechnology

Indian Institute of Technology Delhi

Hauz Khas, New Delhi-110016

ACKNOWLEDGEMENTS

“Showing gratitude is one of the simplest yet most powerful things humans can do for each other.”

-Randy Pausch, The Last Lecture

The work presented in this thesis would not have been possible without the help and support of several people who have been very kind and extended their help at various phase of this research. I would like to take this opportunity to acknowledge them and extend my sincere gratitude for helping me make this PhD thesis a possibility.

First and foremost, I would like to express my indebtedness to my research supervisor **Prof. Prashant Mishra**. His expertise, invaluable guidance, constant encouragement, healthy criticism and most important the freedom to plan and work added considerably to my experience and helped me come a long way. He has been very caring, patient and provided me with necessary laboratory facilities, resources and an excellent atmosphere for doing research. I owe a lot of gratitude to him for always being there for me and I feel privileged to be associated with a person like him during my life.

My special words of thanks to **Prof. Biswajit Kundu** and **Prof. Ashok kumar Patel** for allowing me to use their mammalian cell culture facility, **Prof. Aditya Mittal** for allowing me to use the fluorescence microscope and **Prof. Archana Chugh** for FACS facility. Without their generous help and support, the work done in my thesis would have been an impossible dream. Dozens of people from SBS especially **Dr. Ankit Srivastava, Deepthi Budagavi, Dr. Nisha Ponnapan, Harsha Rohira, Vipul, Anupama Rathi, Kiritika, Priyanka Nair, Debashish, Vivek, Pankhuri, Aarti** and all others have helped me in many aspects and were very kind and supportive throughout my stay in IIT Delhi

I dare not forget to mention the name of two important professors I came across in my life **Dr. Kamlesh Shukla** and **Prof. Satyawati Sharma** who put their faith on me and encouraged me to pursue PhD. I would to convey my heart filled gratitude for their constant motivation and elderly support during the course of my thesis.

My heartfelt gratitude to my seniors and my mentors **Dr. Raju Shankarayan** and **Dr. Swati Jaiswal** who have taught me about the lab culture, experiment planning and execution and stood with me since the beginning till the end. My acknowledgement will never be complete without thanking my lab mates **Dr. Neeti Kalyani, Sanjay Singh, Gaurav Sinsinbar, Dr. Sayoni Das, Dr. Sujata Sinha, Dr. Bhawana Madan, Tushar Dash and Ritu Bhardwaj** for always being there and putting up with me through my good and bad times and making this PhD journey, a delightful experience. I would like to extend my thanks to **Soumya Rajpal** and **Amanpreet kaur Nagpal**, for making my stay delightful with all their love and support during the last stages of my PhD. My special thanks to **Ms. Shraddha Maitra**, my batchmate and close friend, for all the thrill, laughter and late-night study and work. I will always cherish the moments I shared with you in IIT Delhi. I would like to thank **Apurva Agrawal**, research scholar at NBRC Manesar for being an amazing collaborator cum friend. I got to learn a lot about research and data analysis from him, his motivational speeches and positive outlook about everything helped me a lot during this course of time.

I would like to acknowledge the staff of Biochemical Engineering and Biotechnology Department for their innumerable support especially **Mrs. Renu Sethi**, and **Dr. Sumeet Kapoor** for their valuable support and expertise, which has helped me a lot in facilitating my day to day research work.

During my research, I had the pleasure of working with several MTech students, **Divyansh Raj, Shefali Chandolia, Abhinav Kumar, Isha Dhoble, Prateek Kumar and Vinayak Shandilya** whom I guided with their work and they kept the working environment pleasant and conducive. Their assistance during my work is gratefully acknowledged.

I met so many people here in these seven years and few of them managed to secure a special place in my heart and in my life. I would take this opportunity to thank **Rohit Satija, Surabhi Yadav** (my running and swimming partner), **Dr. Arpita Vats, Richa Sharma, Ritesh Agarwal, Dr. Sumit Murab, Dr. Swati Shalini, Tafazzul Hussain, Ajay Luhach, Anant Preet, Suruchi Sethi, Vishal Bhagat, Sakshi Agarwal,**

Moolchand Sigar and many more.... the list is endless...thanks to one and all. I find myself lucky to be surrounded by people like them.

I am grateful to many people in Nanoscale Research facility (NRF), IIT Delhi, who have helped me in getting my analysis done and assisted me in my work. My sincere thanks to **Dr. Amandeep Jindal, Dr. Deepanshu, Dr. Simarjeet Singh, Dr. Sharmila, Vaishali Sethi, Dr. Athulya Aravind and Ojaswani mam** for making the facilities available to me during the research work.

I owe a lot to my parents and my parents-in-law, who mean world to me. They have always encouraged me and helped me at every stage of my personal and academic life and longed to see this achievement come true. Thank you, mom and dad, for showing faith in me and giving me the liberty to continue what I desired. I am grateful to my cousin **Mrs. Khushboo Varanwal** and my brother-in-law **Mr. Rahul Kumar Varanwal**, for being this great support ever since they have moved to Delhi and I owe them so much for their care and hospitality.

I am very indebted to my husband **Mr. Parag Raj Meshram** and my elder brother **CA Sourabh Goel**, who have been a constant source of support (both emotionally and financially), love and encouragement throughout the course of this thesis. My husband, I can't thank him enough for his endless love, patience and never-ending motivation even when he bore the brunt of my moods and absence. He has constantly encouraged me when the tasks seemed tough and have demonstrated rare and amazing patience throughout my lengthy working sessions over the last one year.

I acknowledge the Council of Scientific and Industrial Research (CSIR), Government of India for providing me the necessary funding and fellowship to pursue research at IIT Delhi.

In the end I would like to thank the Almighty for seeing me all through.

Surbhi Goel

ABSTRACT

Now-a-days plant-based phytochemicals are gaining much importance over conventional therapeutics owing to their multifunctionality and low toxicity. Thymoquinone (TQ), is one such phytochemicals which possess remarkable anti-cancer activity and known for its anti-inflammatory, anti-oxidant, anti-fungal and anti-bacterial activity. It is isolated from the volatile oil fraction of *Nigella sativa*. In the present study, antibacterial, antibiofilm activity of TQ and mechanism of action has been explored. Antibacterial activity of TQ was studied by determining minimum inhibitory concentration, minimum bactericidal concentration, time-kill assay and post-antibiotic effect against two Gram-negative and two Gram-positive bacteria. The minimum inhibitory concentration of TQ was found to be in the range of 1.56 µg/ml to 100 µg/ml. TQ treated bacterial cells at MIC were visualized using scanning electron microscopy which revealed changes in cell morphology, cell lysis and cell size reduction. Live/dead imaging confirmed the bactericidal activity of TQ as treated bacteria showed uptake of ethidium bromide over acridine orange. Selectivity of TQ towards bacterial cell was observed by studying its toxicity towards HaCaT (human keratinocytes) cell line by MTT assay. IC₉₀ value was found to be 50µg/ml which was higher than that of MIC_{bacteria} (except for MIC of *E. coli*). TQ also showed promising anti-biofilm activity against both Gram-negative (*E. coli* and *P. aeruginosa*) and Gram-positive bacteria (*B. subtilis* and *S. aureus*), which was studied by crystal violet assay, MTT assay, CFU counting and SEM. TQ also exhibited anti-biofilm activity against preformed biofilm i.e. 6 h old and 24 h old. For understanding the antibacterial mechanism of action of TQ, DiSC₃, NPN and ROS assays were performed. DiSC₃ and NPN assays have not shown any membrane damage caused by TQ. However, bacterial cells treated with TQ at MIC showed increased dichlorofluorescein fluorescence suggesting the production of reactive oxygen species. This was further confirmed by incubating bacteria at

MIC of TQ in the presence of reduced glutathione, a known ROS scavenger. Glutathione caused attenuation of TQ's antibacterial activity confirming that ROS generation could be the probable mechanism for TQ antibacterial action. In addition to TQ's antibacterial activity its potential application as anticancer agent has also been studied. In this study, nanoencapsulation of TQ in PLGA and mesoporous silica nanoparticle was carried out, to overcome the limitations of using TQ in its free form. PLGA was employed as a nanocarrier because of its biocompatibility, biodegradability and property of sustained release of drug over a long period of time. Iron-oxide nanoparticles of size 6-10 nm has also been incorporated in PLGA along with TQ to obtain the benefit of targeted drug delivery under the influence of external magnetic field and also modulate of drug release kinetics employing hyperthermia. On the other hand, advantages with mesoporous silica nanoparticles are non-toxicity, high surface area to volume ratio, high porosity and chemical stability which leads to high loading efficiency of hydrophobic drugs. Successful encapsulation of TQ within PLGA and mesoporous silica nanoparticles has been achieved with size in the range of 100 nm- 300 nm. Both TQ nanoformulations showed cytotoxicity against HeLa and MCF-7 cell lines at lower concentration of TQ as compared to the free TQ. Anticancer activity of TQ loaded PLGA and MSNPs were studied by DAPI staining and Annexin V-FITC/PI staining and it was found that both nanoformulations exhibit anticancer activity by inducing apoptosis. While PLGA appears to be ideal formulation for long term delivery of TQ, mesoporous silica nanoparticles have shown advantages of high loading efficiency, low cost and short-term delivery of hydrophobic drugs.

सार

आजकल पौधों से प्राप्त किये गए फाइटोकेमिकल्स अपने बहुआयामी और कम विषाक्तता के कारण परंपरागत चिकित्सा पर अधिक महत्व प्राप्त कर रहे हैं। थाइमोक्विनोन, एक ऐसा फाइटोकेमिकल् है जिसमें उल्लेखनीय एंटी-कैंसर गतिविधि होती है और इसको एंटीइंफ्लामेटरी, एंटीऑक्सीडेंट, एंटीफंगल और एंटीबैक्टीरियल गतिविधि के लिए जाना जाता है। यह निगेला सटाइवा के वाष्पशील तेल अंश से अलग किया है। वर्तमान अध्ययन में, थाइमोक्विनोन की एंटीबैक्टीरियल, एंटीबायोफिल्म गतिविधि और क्रिया के तंत्र की खोज की गई है। थाइमोक्विनोन की जीवाणुरोधी गतिविधि का अध्ययन, दो ग्राम-निगेटिव और दो ग्राम-पॉजिटिव बैक्टीरिया के खिलाफ, न्यूनतम अवरोधक सांद्रता, न्यूनतम जीवाणुनाशक सांद्रता, टाइम किल परख का अनुमान लगा के किया गया है, जिसमें थाइमोक्विनोन की न्यूनतम अवरोधक सांद्रता 1.56 µg/ml से 100 µg/ml तक पायी गई। बैक्टीरियल कोशिकाओं में थाइमोक्विनोन के न्यूनतम अवरोधक सांद्रता से ट्रीटमेंट के बाद के असर का अध्ययन करने के लिए, स्कैनिंग इलेक्ट्रॉन माइक्रोस्कोपी का उपयोग करके देखा गया, जिसमें कोशिका अपघटन, कोशिकाओं की आकृति और आकार में बदलाव पाया गया। जीवित / मृत इमेजिंग से भी थाइमोक्विनोन की जीवाणुनाशक गतिविधि की पुष्टि की गयी, जिसमें थाइमोक्विनोन से ट्रीटमेंट के बाद बैक्टीरियल कोशिकाओं ने एक्रिडीन ऑरेंज पर इथिडियम ब्रोमाइड का अंतर्ग्रहण दिखाया। सेलेक्टिव टॉक्सिसिटी की परख के लिए HaCaT (मानव केराटिनोसाइट्स) कोशिकाओं की ओर, थाइमोक्विनोन की विषाक्तता का अध्ययन एम. टी. टी. परख द्वारा करके देखा गया, इस अध्ययन में IC₅₀ सांद्रता 50 µg/ml पाया गया जो कि न्यूनतम अवरोधक सांद्रता बैक्टीरिया से अधिक है (ई. कोलाई के न्यूनतम अवरोधक सांद्रता को छोड़कर)। थाइमोक्विनोन ने ग्राम-निगेटिव और ग्राम-पॉजिटिव दोनों ही बैक्टीरिया के खिलाफ एंटीबायोफिल्म गतिविधि को भी दिखाया, जिसका अध्ययन क्रिस्टल वायलेट परख, एम. टी. टी. परख, कॉलोनी फॉर्मिंग यूनिट गिनती और स्कैनिंग इलेक्ट्रॉन माइक्रोस्कोपी द्वारा किया गया। थाइमोक्विनोन ने सुनिर्मित बायोफिल्म, यानी 6 घंटे पुरानी और 24 घंटे पुरानी के खिलाफ भी एंटी-बायोफिल्म गतिविधि दर्शायी। थाइमोक्विनोन के जीवाणुरोधी तंत्र को समझने के लिए, DISC₃, N-फिनाइल-1-नाफ्थिलाअमिन और प्रतिक्रियाशील ऑक्सीजन प्रजातियां परख द्वारा अध्ययन किया गया। थाइमोक्विनोन के

ट्रीटमेंट के पश्चात्, $DISC_3$ और N-फिनाइल-1-नाफ्थिलाअमिन परख द्वारा कोई मेम्ब्रेन क्षति नहीं प्राप्त हुई। हालांकि, न्यूनतम अवरोधक सांद्रता में थाइमोक्विनोन के साथ ट्रीटमेंट किए गए जीवाणु कोशिकाओं में डी.सी.एफ.-डी.ए. परख द्वारा प्रतिक्रियाशील ऑक्सीजन प्रजातियों के उत्पादन में वृद्धि देखी गया। ग्लूटाथिओन की उपस्थिति में थाइमोक्विनोन की एंटीबैक्टीरियल गतिविधि की प्रतिबंधन की पुष्टि हुई और इस अध्ययन से ये पुष्टि होती है कि थाइमोक्विनोन द्वारा प्रतिक्रियाशील ऑक्सीजन प्रजातियों का उत्पादन, एंटीबैक्टीरियल क्रिया के लिए संभावित तंत्र हो सकता है। थाइमोक्विनोन की जीवाणुरोधी गतिविधि के अलावा एंटीकैंसर एजेंट के रूप में इसके संभावित अनुप्रयोग का भी अध्ययन किया गया है। इस अध्ययन में, थाइमोक्विनोन का नैनोएंकैप्सूलेशन, पी.एल.जी.ए और मेसोपोरस सिलिका नैनोकण में किया गया, जो की थाइमोक्विनोन के मुक्त रूप में उपयोग करने की सीमाओं को दूर करने के लिए सहायक साबित होगी। पी.एल.जी.ए को निम्न कारणों की वजह से नैनोकैरियर के रूप में नियोजित किया गया: लंबे समय तक दवा का निरंतर रिलीज, बायोकम्पेटिबिलिटी और बायोडिग्रेडेबिलिटी। बाहरी चुंबकीय क्षेत्र के प्रभाव में लक्षित दवा वितरण के लाभ प्राप्त करने के लिए थाइमोक्विनोन के साथ पी.एल.जी.ए में 6-10 nm आकार के आयरन-ऑक्साइड नैनोकणों को भी शामिल किया गया है और हाइपरथेरमिआ द्वारा दवा के रिलीज काइनेटिक्स का भी संशोधन किया गया है। दूसरी तरफ, मेसोपोरस सिलिका नैनोकणों के साथ, गैर-विषाक्तता, उच्च सतह क्षेत्र / मात्रा अनुपात, उच्च संरध्रता और रासायनिक स्थिरता जैसे फायदे हैं जो हाइड्रोफोबिक दवाओं की उच्च लोडिंग दक्षता के लिए उपयोगी हैं। पी.एल.जी.ए और मेसोपोरस सिलिका नैनोकणों के भीतर थाइमोक्विनोन के सफल समावेशन से 100 nm -300 nm की सीमा में आकार के नैनोकण प्राप्त किये गए। मुक्त थाइमोक्विनोन की तुलना में दोनों ही थाइमोक्विनोन नैनो-फॉर्मूलेशन ने थाइमोक्विनोन की कम सांद्रता पर HeLa और MCF-7 कोशिकाओं के खिलाफ साइटों टोक्सिसिटी दिखायी। थाइमोक्विनोन लोड किए गए पी.एल.जी.ए और मेसोपोरस सिलिका नैनोकणों की एंटीकैंसर गतिविधि का अध्ययन डी.ए.पी.आई. स्टेनिंग और अन्नेक्सीन V- एफ.आई.टी.सी. और प्रोपीडियम आयोडाइड स्टेनिंग द्वारा किया गया और यह पाया गया कि नैनो-फॉर्मूलेशन एपोप्टोसिस को प्रेरित करके एंटीकैंसर गतिविधि दर्शाते हैं। पी.एल.जी.ए. थाइमोक्विनोन की लंबी अवधि के वितरण के लिए आदर्श फॉर्मूलेशन प्रतीत होता है, मेसोपोरस सिलिका नैनोकणों ने हाइड्रोफोबिक दवाओं की उच्च लोडिंग दक्षता, कम लागत और अल्पकालिक वितरण के फायदे दिखाए हैं।

TABLE OF CONTENTS

CERTIFICATE.....	I
ACKNOWLEDGEMENTS	III
ABSTRACT.....	VII
LIST OF FIGURES	XV
LIST OF TABLES	XXIII
LIST OF ABBREVIATIONS	XXV
1 INTRODUCTION	1
1.1 Objectives.....	3
2 LITERATURE REVIEW	5
2.1 Phytochemicals as a therapeutics	5
2.2 Thymoquinone (TQ).....	8
2.3 Chemical characteristics of TQ	10
2.4 Medicinal properties of TQ.....	11
2.4.1 TQ as an antibacterial agent	11
2.4.2 TQ as an antibiofilm agent	13
2.4.3 TQ as antifungal agent.....	15
2.4.4 TQ as an anticancer agent.....	15
2.4.5 TQ as an anti-inflammatory agent	17
2.4.6 TQ as anti-oxidant, cyto and hepatoprotective agent	18
2.4.7 TQ as a pro-oxidant agent	19
2.5 Limitations of TQ as a therapeutic agent	21
2.6 Nanoparticle drug delivery systems	21
2.7 PLGA as a delivery vehicle for TQ	23
2.7.1 PLGA nanoparticles as delivery system for hydrophobic drugs	26

2.7.2	Multifunctional drug delivery vehicles.....	26
2.7.3	Incorporating multifunctionality using magnetic (iron oxide) nanoparticles	27
2.8	Mesoporous silica nanoparticles as delivery vehicle for TQ.....	30
2.8.1	Mechanism for the synthesis of mesoporous silica nanoparticles	30
2.8.2	Mesoporous silica nanoparticles as delivery system for hydrophobic drugs	32
2.9	Nano-formulations of TQ	32
3	MATERIALS AND METHODS.....	37
3.1	Major equipment and chemicals	37
3.2	Bacterial strains, cell line, growth media and other chemicals.....	37
3.3	Antimicrobial assays.....	37
3.3.1	Minimum inhibitory concentration (MIC) and Minimum bactericidal concentration (MBC) determination	37
3.3.2	Live/Dead imaging	38
3.3.3	Post antibiotic effect (PAE).....	38
3.3.4	Time-kill assay	39
3.4	Field emission scanning electron microscopy (FESEM) of bacteria treated with TQ	39
3.5	Biofilm inhibition assay	40
3.5.1	Effect of TQ on biofilm formation	40
3.5.2	Scanning electron microscopy of the anti-biofilm activity of TQ.....	40
3.5.3	Effect of TQ on preformed biofilm by crystal violet assay	41
3.5.4	Effect of TQ on biofilm cell viability/metabolic activity (MTT assay)	41
3.5.5	Effect of TQ on biofilm cell viability (CFU method)	42
3.6	Cytotoxicity study on keratinocytes	42
3.7	Study of mechanism of action of TQ.....	42
3.7.1	Membrane depolarization assay	42
3.7.2	Outer membrane permeability assays.....	43
3.7.3	Reactive oxygen species detection	44
3.7.4	Attenuation of TQ activity by reduced glutathione	44

3.8	Preparation of TQ loaded nanoparticles	44
3.8.1	Preparation of oleic acid coated iron-oxide nanoparticles (IONP).....	44
3.8.2	Preparation of TQ loaded and TQ-IONP loaded and coumarin-6 loaded PLGA nanoparticles.....	45
3.8.3	Separation of PLGA nanoparticles by differential centrifugation.....	46
3.8.4	Preparation of mesoporous silica nanoparticles (MSNPs)	47
3.8.5	Preparation of TQ and coumarin-6 loaded mesoporous silica nanoparticles	48
3.9	Characterization of nanoparticles	49
3.9.1	Size determination of nanoparticles using dynamic light scattering	49
3.9.2	TEM of nanoparticles	49
3.9.3	SEM of nanoparticles	49
3.9.4	FTIR.....	50
3.9.5	Powder X-ray diffraction of IONP	50
3.9.6	AGM.....	50
3.9.7	Loading and encapsulation efficiency	50
3.9.8	<i>In vitro</i> release study of TQ from nanoparticles	51
3.10	Anticancer studies of nanoparticles	51
3.10.1	Cellular uptake of TQ loaded nanoparticles	51
3.10.2	Cytotoxicity against MCF-7 and Hela cell lines	52
3.10.3	Apoptosis study by DAPI staining in cancer cells by nanoparticle preparation ...	52
3.10.4	Apoptosis study using Annexin-V-FITC and PI staining with fluorescence microscopy	53
3.10.5	Transwell migration assay of cancer cells treated with TQ loaded mesoporous silica nanoparticles.....	53
3.10.6	ROS detection assay in cancer cells treated with TQ loaded mesoporous silica nanoparticles.....	54
3.11	Statistical analysis:.....	55
4	RESULTS AND DISCUSSION.....	57
<hr/>		
.....		57
4.1	To evaluate antibacterial, anti-biofilm activity of TQ and explore its mechanism of action.....	57

4.1.1	Antibacterial activity of TQ.....	58
4.1.2	Cytotoxicity of TQ on HaCaT (keratinocytes) cell line	65
4.1.3	Anti-biofilm activity of TQ	67
4.1.4	Mechanism of action of TQ:.....	78
4.1.5	Effect of reduced glutathione on TQ antibacterial activity	84
<hr/>		
.....		87
4.2	To synthesize and characterize TQ and IONP loaded PLGA nanoparticles and their anticancer activity.....	87
4.2.1	Synthesis and characterization of Iron-oxide nanoparticles (IONP).....	88
4.2.2	Synthesis and characterization of IONP loaded PLGA nanoparticles	94
4.2.3	Separation of PLGA nanoparticles on the basis of size – By differential Centrifugation.....	96
4.2.4	Anticancer activity of PLGA nanoparticles.....	102
<hr/>		
.....		109
4.3	To synthesize and characterize TQ loaded mesoporous silica nanoparticles and their anticancer activity.....	109
4.3.1	Synthesis and characterization of Mesoporous silica nanoparticles.....	109
4.3.2	Cellular uptake of mesoporous silica nanoparticles	112
4.3.3	Anticancer activity of TQ-MSNPs	113
5	CONCLUSION AND SUMMARY	125
6	REFERENCES	129
APPENDIX I		158
APPENDIX II.....		160
APPENDIX III		162
AUTHOR’S BIOGRAPHY.....		167

LIST OF FIGURES

Figure 2.1: Chemical structure of Thymoquinone (TQ).....	9
Figure 2.2: Graphical representation of quinone redox cycle mechanism.....	20
Figure 2.3: Applications of nanoparticles in medicine	22
Figure 2.4: Degradation of PLGA by hydrolysis to its monomeric unit lactic acid and glycolic acid which then enters Krebs cycle and gets eliminated as CO ₂ and H ₂ O (Makadia and Siegel 2011).	25
Figure 2.5: Schematic illustration of drug release from PLGA nanoparticles by magnetic hyperthermia	29
Figure 2.6: Hydrolysis and condensation step in mesoporous silica nanoparticle synthesis	31
Figure 3.1: Graphical representation of methods for obtaining different sized mono dispersed particles by differential centrifugation.	47
Figure 3.2: Graphical representation of preparation of mesoporous silica nanoparticles.....	48
Figure 3.3: Graphical representation of loading of TQ in mesoporous silica nanoparticles	48
Figure 4.1: Live/Dead imaging of bacterial cells after TQ treatment. Images were taken after proper washing with PBS (pH 7.4) at 40 X magnification. After 18 h, control cells showed uptake of only acridine orange (green fluorescence) while TQ treated cells showed uptake of ethidium bromide (red fluorescence)	61
Figure 4.2: Time-kill curves: Gram-negative strains: <i>P. aeruginosa</i> ATCC 14886 (a) and <i>E. coli</i> ATCC 25922 (b); Gram-positive strains: <i>S. aureus</i> ATCC 9144 (c) and <i>B. subtilis</i> ATCC 6633 (d) incubated with TQ at various concentrations. Data is represented as mean ± SD of three independent experiments. The statistical significance was determined by student t-test (p < 0.05).	62
Figure 4.3: FESEM images of <i>S. aureus</i> : (a) Control Cells, (b) Cells treated with TQ at 2X MIC showing dents and blebbing (c) Cells treated with TQ at 4X MIC showing cell lysis. <i>E. coli</i> :(d) Control cells (e) Cells treated with TQ at	

MIC showing smaller cells with dents (f) Cells treated with TQ at 2X MIC showing cell lysis. Bacterial cells with TQ were incubated at 37 °C for 2 h. Images were taken at 50,000 X magnification. Scale bar represents 2 μm.65

Figure 4.4: Percentage cell viability of HaCaT cell line treated with TQ (0.78 μg/ml - 100 μg/ml) incubated for 24 h at 37 °C. The experiments were performed in triplicates and repeated three times (N=3). Data is given as mean ± SD and ** (p<0.01) determined by student t-test analysis.66

Figure 4.5:(a) Anti-biofilm formation activity of TQ on *P. aeruginosa*, *E. coli*, *S. aureus* and *B. subtilis* by crystal violet assay. The concentration of TQ for all bacteria other than *E. coli* was 0.78 - 100 μg/ml and for *E. coli* concentration used was 7.8 – 1000 μg/ml shown inside parentheses. All the experiments were performed in duplicates and repeated three times. Data is represented as mean ± SD of three independent experiments. (b) Viable cell counts present in biofilm after TQ treatment was calculated by plating method. Cell counts was monitored with three different concentration of TQ 2 X BIC₉₀, BIC₉₀ and 0.5 X BIC₉₀ viable cell numbers were represented as log (CFU/ml).....69

Figure 4.6: Antibiofilm formation activity of TQ on *P. aeruginosa*, *E. coli*, *S. aureus* and *B. subtilis* by MTT assay. The concentration of TQ for all bacteria other than *E. coli* was 0.78 - 100 μg/ml and for *E. coli* concentration used was 7.8 – 1000 μg/ml shown inside parentheses. All the experiments were performed in triplicates and repeated three times. Data is represented as mean ± SD of three independent experiments.70

Figure 4.7: SEM images of bacteria in biofilm inhibition assay. Bacterial cells were incubated with TQ BIC₉₀ concentration for 24 h to allow for biofilm formation. Control cells were incubated without TQ. Images were taken at 10,000 X magnification. Scale bar represents 2 μm.72

Figure 4.8:(a) Young (6 h) biofilm degradation activity of TQ on *P. aeruginosa*, *E. coli*, *S. aureus* and *B. subtilis* by crystal violet assay. The concentration of TQ was used in the range of 1.9 - 1000 μg/ml. All the experiments were performed in triplicates and repeated three times. Data is represented as mean ± SD of three independent experiments. (b) Viable cell counts present

in biofilm after TQ treatment was calculated by plating methods. Cell counts were taken with three different concentration of TQ 2 X MBEC₉₀, MBEC₉₀ and 0.5 MBEC₉₀ viable cell numbers were represented as log (CFU/ml). Data is represented as mean ± SD of three independent experiments.73

Figure 4.9: Young (6 h) biofilm degradation activity of TQ on *P. aeruginosa*, *E. coli*, *S. aureus* and *B. subtilis* by MTT assay. The concentration of TQ was used in the range of 1.9 - 1000 µg/ml. All the experiments were performed in triplicates and repeated three times. Data is represented as mean ± SD of three independent experiments.....75

Figure 4.10: (a) Mature (24 h old) biofilm degradation activity of TQ on *P. aeruginosa*, *E. coli*, *S. aureus* and *B. subtilis* studied by crystal violet assay. The concentration of TQ was used in the range of 1.9 - 1000 µg/ml. All the experiments were performed in triplicates and repeated three times. Data is represented as mean ± SD of three independent experiments. (b) Viable cell counts present in biofilm after TQ treatment was calculated by plating methods. Cell counts were taken with three different concentration of TQ 2 X MBEC₉₀, MBEC₉₀ and 0.5 MBEC₉₀ viable cell numbers are represented as log (CFU/ml). Data is represented as mean ± SD of three independent experiments.....76

Figure 4.11: Mature (24 h) biofilm degradation activity of TQ on *P. aeruginosa*, *E. coli*, *S. aureus* and *B. subtilis* by MTT assay. The concentration of TQ was used in the range of 1.9 - 1000 µg/ml. All the experiments were performed in triplicates and repeated three times. Data is represented as mean ± SD of three independent experiments.....77

Figure 4.12: DiSC₃ assay for *E. coli*: (a) complete demonstration of experiment where 2 is point of cell addition, 3 is point of dye addition and 4 is Point of TQ addition. After TQ addition, increase in fluorescence was not observed till 30 min. DiSC₃ assay of *E. coli* incubated with 2X MIC (b), 4X MIC (c) and 8X MIC (d) of TQ.79

Figure 4.13: NPN assay (a) Buffer + NPN dye (b) Buffer + NPN + TQ. Fluorescence was measured for 25 min. (c) NPN assay of <i>P. aeruginosa</i> (d) NPN assay of <i>E. coli</i> . Increase in fluorescence was not observed even after 30 min.	80
Figure 4.14: ROS production assay of <i>P. aeruginosa</i> ATCC 14886 (a), <i>E. coli</i> ATCC 25922 (b), <i>S. aureus</i> ATCC 9144 (c) and <i>B. subtilis</i> ATCC 6633 (d) incubated with TQ at varying concentration for 24 h. Data are represented as Mean \pm SD of three independent experiments. C1-Control without DCF-DA, C2-Control with DCF-DA. TQ concentration ranged from 0.39 μ g/ml to 100 μ g/ml (39 μ g/ml to 1000 μ g/ml in case of <i>E. coli</i>). * $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$ determined by student t-test analysis.	83
Figure 4.15: Attenuation of TQ antibacterial activity by adding 5 mM Glutathione as determined by measuring OD ₆₀₀ at MIC, 2X MIC, 4X MIC and 0.5 X MIC: (a) <i>P. aeruginosa</i> (b) <i>E. coli</i> (c) <i>S. aureus</i> and (d) <i>B. subtilis</i> . Data are represented as Mean \pm SD of three independent experiments.	84
Figure 4.16: Attenuation of TQ antibacterial activity as determined by counting colony forming units at MIC, 2X MIC and 0.5X MIC (also 4X MIC in case of <i>S. aureus</i>) by adding 5mM glutathione: (a) <i>P. aeruginosa</i> (b) <i>E. coli</i> (c) <i>S. aureus</i> and (d) <i>B. subtilis</i> . Data are represented as Mean \pm SD of three independent experiments.....	85
Figure 4.17: TEM images of Iron-Oxide nanoparticles. (a) Image were taken at 19,500 X magnification. Scale bar represents 100 nm. (b) Image were taken at 70,000 X magnification. Scale bar represents 50 nm.....	89
Figure 4.18: TGA curve for iron-oxide nanoparticle coated with oleic acid showing 16.9% percentage weight loss indicative of single layered coating of oleic acid	90
Figure 4.19: Solubility test of oleic acid coated iron oxide nanoparticles.....	91
Figure 4.20: AGM showing saturation magnetization for oleic Acid coated IONP.....	92
Figure 4.21: XRD diffraction pattern of OA-IONP.....	92
Figure 4.22: FTIR spectra of bare IONP (a) and OA-IONP (b). Peaks at 574 cm^{-1} corresponds to the characteristic peak of Fe-O bond. In OA-IONP	

nanoparticle, peaks at 2922 cm^{-1} , characteristic peaks of CH_2 stretching in oleic acid was observed, which was absent in case of bare IONP.	93
Figure 4.23: Particle size of IONP-PLGA nanoparticles obtained by (a) single emulsion solvent evaporation method (b) double emulsion solvent evaporation method.	95
Figure 4.24: TEM images of IONP loaded PLGA nanoparticle obtained by single emulsion method. Size of nanoparticle were in the range of 200-300nm. (a) Scale bar represents 500 nm. (b) scale bar represents 50 nm.	96
Figure 4.25: The graph showing percentage of different size fraction of nanoparticles obtained in supernatant fraction after differential centrifugation at 8000 X g for 15 min. The percentage of particles in the range of 100 – 200 nm: (a) PLGA (blank) – 98% with $\text{PDI} = 0.06 \pm 0.02$ (b) PLGA + IONPs+TQ – 97% with $\text{PDI} = 0.105 \pm 0.04$ (Appendix III)	97
Figure 4.26: The graph showing percentage of different size fraction of nanoparticles obtained in pellet fraction after differential centrifugation at 8000 X g for 15 min. The percentage of particles in the range of 200 - 300 nm: (a) PLGA + IONPs +TQ– 97% with $\text{PDI} = 0.04 \pm 0.02$. (b) PLGA (blank) – 97% with $\text{PDI} = 0.037 \pm 0.01$. (Appendix III)	97
Figure 4.27: SEM images of TQ and IONP loaded PLGA nanoparticles obtained after centrifugation at 8000 X g for 15 min. (a) Particles in size range of 100-200nm (b) Particles in size range of 200-300 nm. Images were taken at 30,000 X magnification. Scale bar represent 200 nm.	98
Figure 4.28: Differential scanning calorimetry of PLGA in free form and in the form of nanoparticle. Samples were heated at the rate of $10\text{ }^\circ\text{C}$ per min from 0 – 250 $^\circ\text{C}$ under nitrogen flow.	99
Figure 4.29: Magnetic properties of IONP-PLGA nanoparticles (a) IONP-PLGA of size 100 - 200 nm and (b) IONP-PLGA of size 200-300 nm.	101
Figure 4.30: FTIR analysis of IONP-PLGA nanoparticles.	101
Figure 4.31: DAPI staining of HeLa cells following treatment with IC_{50} concentration of TQ, TQ-PLGA NPs and IONP-TQ-PLGA NPs for 24 h at $37\text{ }^\circ\text{C}$	106

Figure 4.32:DAPI staining of MCF-7 cells following treatment with IC ₅₀ concentration of TQ, TQ-PLGA NPs and IONP-TQ-PLGA NPs for 24 h at 37 ° C.	106
Figure 4.33: Annexin V-FITC and PI staining of HeLa after 24 h treatment with different formulations of PLGA nanoparticles at IC ₅₀ concentrations. Images were taken at 10X magnification.	107
Figure 4.34: Annexin V-FITC and PI Staining of MCF-7 after 24 h treatment with different formulations of PLGA nanoparticles at IC ₅₀ concentrations. Images were taken at 10X magnification.	108
Figure 4.35: Characterization of TQ-MSNPs: Particle Size graph (a); Particle size distribution (b); FESEM image (magnification- 50,000X, Scale -2 μM) (c); TEM image (scale – 100 nm) (d); FTIR spectra of BMSNP and TQ-MSN(e); In vitro release pattern of TQ from TQ loaded MSNPs (f).....	111
Figure 4.36: Qualitative evaluation of uptake of coumarin loaded mesoporous silica nanoparticles in MCF-7 cells and HeLa cells at 37 °C incubated for different time periods.	113
Figure 4.37: Concentration dependent cytotoxicity of TQ loaded mesoporous silica nanoparticles towards HeLa and MCF-7 cell. All the experiments were performed in duplicates and are repeated thrice. Data are represented as mean ± SD of three independent experiments.	114
Figure 4.38: Apoptosis study by DAPI staining after treatment of MCF-7 and HeLa cell lines with TQ, TQ-MSNPS and BMSNPs for 24 h at 37 °C.	115
Figure 4.39: Annexin V-FITC/PI labelling of HeLa cells after treatment with IC ₅₀ TQ, IC ₅₀ TQMSNP and IC ₅₀ BMSNP for 24 h at 37° C.	117
Figure 4.40:Annexin V-FITC/PI labelling of MCF-7 cells after treatment with IC ₅₀ TQ, IC ₅₀ TQMSNP and IC ₅₀ BMSNP for 24 h at 37° C.	118
Figure 4.41: Transwell migration assay of HeLa and MCF-7 cell lines: Cells were seeded in the upper chambers of transwell and treated with different test samples for 24 h at 37 °C. Cells that undergo invasion were fixed and stained with crystal violet, followed by visualization at 20X magnification	119
Figure 4.42: Graph showing migration of cancer cells across transwell chamber with 8 μm pores size coated with basement membrane matrix after treatment with	

respective agents. All experiments were performed twice independently, and total 5 images were captured for each sample, Data is represented as mean percent migration \pm SD. 120

Figure 4.43: Detection of ROS generation using DCF-DA (an oxidant – sensitive fluorescent probe). ROS generation on (a) MCF-7 cell line and (b) HeLa cell line was studied by treating cells with IC50 concentration of TQ and TQ loaded MSNPs. Blank MSNP (BMSNP) were used at a concentration corresponding to that of TQMSNPs. Also, NAC at 4mM was added along with test samples and H₂O₂ 0.03% was used as ROS inducer, a positive control 122

Figure 4.44: Effect of NAC on the cytotoxic effect of TQ and TQMSNP on (a) and (c) HeLa and (b) and (d) MCF-7 cell line. Cell lines were treated with different concentration of TQ (0.78 μ g/ml – 100 μ g/ml) alone and with combination of TQ and 4 μ M NAC at 37 °C for 24 h. Following which MTT assay was performed to study the cytotoxicity. Data in the graph is represented as mean \pm SD. 123

LIST OF TABLES

Table 2.1: List of some plants derived therapeutics used as antimicrobials	6
Table 2.2:Quinone compounds from natural source with both anticancer and antimicrobial activity	7
Table 2.3: Important chemical and physical properties of Thymoquinone (Adapted from Darakhshan et al. 2015).....	10
Table 2.4: Reported MIC/MBC values of TQs ($\mu\text{g/ml}$) against E. coli, S. aureus, B. subtilis and P. aeruginosa.....	12
Table 2.5: FDA approved formulations of PLGA (adapted from (Mundargi et al. 2008; Danhier et al. 2012; Kerimoglu and Alarcin 2012).....	24
Table 2.6: Nanoparticles based drug delivery methods employed for TQ	33
Table 4.1:Minimum inhibitory concentration and minimum bactericidal concentration ($\mu\text{g/ml}$) of TQ, kanamycin and chloramphenicol.....	59
Table 4.2: MIC_{super} and MBC_{super} of TQ at high cell density (10^8 CFU/ml).....	60
Table 4.3: Post antibiotic effect of TQ in (h) and other control antibiotics (kanamycin and chloramphenicol) determined on four bacterial strains using 5X MIC.....	63
Table 4.4: Selectivity i.e. the ratio of IC₉₀HaCaT cell line and MIC_{bacteria}, of TQ towards bacterial cells over animal cell line.	67
Table 4.5: Zeta potential measurement of bacterial cells after TQ treatment.....	81
Table 4.6: First and second weight loss based on TGA curves of oleic acid coated Iron oxide nanoparticles synthesized by co-precipitation method	89

Table 4.7: Inhibitory concentration of TQ, TQ-PLGA and IONP-TQ-PLGA NPs against HeLa and MCF-7 cell line. The experiments were conducted in duplicates and were repeated thrice. The inhibitory concentrations are reported in $\mu\text{g/ml}$ 103

Table 4.8: Cytotoxic concentration of TQ and TQ-MSNPs against HeLa and MCF-7 cell line. The experiments were performed in duplicates and are repeated thrice, and concentrations are reported in $\mu\text{g/ml}$ 114

LIST OF ABBREVIATIONS

AGM	Alternate gradient magnetometer
AO	Acridine orange
ATCC	American Type culture collection
BIC	Biofilm inhibitory concentration
BMSNPs	Blank mesoporous silica nanoparticles
CFU	Colony forming units
CLSI	Clinical and Laboratory Standards Institute
Co	Coumarin-6
Co-MSNPs	Coumarin-6 loaded mesoporous silica nanoparticles
CTAB	Cetyltrimethylammonium bromide
DAPI	(4',6-diamidino-2-phenylindole)
DCF	2,7-dichlorofluorescein
DCF-DA	2',7'-dichlorodihydrofluorescein diacetate
DCFH	2,7-dichlorodihydrofluorescein
DCM	Dichloromethane
DiSC ₃ (5)	3,3'- dipropylthiacarboyanine
DLS	Dynamic Light Scattering
DMEM	Dulbecco's Modified Eagle's Medium
DMSO	Dimethyl sulfoxide
EtBr	Ethidium bromide
EDTA	Ethylene diamine tetra acetic acid
FBS	Fetal bovine serum
FDA	Food and Drug Administration

FESEM	Field emission scanning electron microscope
FI	Fluorescence intensity
FITC	Fluorescein isothiocyanate
FTIR	Fourier-transform infrared spectroscopy
g	Relative centrifugal force
GSH	Reduced Glutathione
h	Hour
HaCaT	Immortalized human epidermal keratinocytes
HeLa	Human epithelial cervical adenocarcinoma
HEPES	4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
IC ₅₀	Concentration at which 50% inhibition takes place
IC ₉₀	Concentration at which 90% inhibition takes place
IONP	Iron-oxide nanoparticles
IONP-PLGA	Iron oxide nanoparticle loaded PLGA nanoparticles
LB	Luria broth
m	Milli
M	Molar
mM	Millimolar
ml	Milliliter
mg	Milligram
MBC	Minimum bactericidal concentration
MBEC	Mature biofilm eradication concentration
MCF-7	Human epithelial breast adenocarcinoma
MCM 41	Mobil composition of matter No. 41
MHA	Mueller hinton agar
MHB	Mueller hinton broth

MIC	Minimum inhibitory concentration
Ms	Saturation magnetization
MSNPs	Mesoporous silica nanoparticles
MTT	3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
nm	Nanometer
NP	Nanoparticle
NPN	1-N-phenyl naphthylamine
NPs	Nanoparticles
OD	Optical density
OA	Oleic acid
OA-IONP	Oleic acid coated iron oxide nanoparticles
OH^\cdot	Hydroxyl radical
PAE	Post antibiotic effect
PBS	Phosphate buffer saline
PDI	Polydispersity index
PI	Propidium iodide
PLGA	Poly (D, L-lactide-co-glycolic) acid
PS	Phosphatidylserine
PVA	Poly vinyl alcohol
ROS	Reactive oxygen species
Rpm	Revolutions per minute
RPMI	Roswell Park Memorial Institute
s	seconds

SD	Standard deviation
SEM	Scanning electron microscope
SPION	Superparamagnetic iron oxide nanoparticles
TEM	Transmission electron microscope
TEOS	Tetraethyl orthosilicate
TQ	Thymoquinone
WHO	World Health Organization
w/v	weight per unit volume
v/v	Volume per unit volume
μ	Micro
μl	Microliter
μg	Microgram
°	Degree Celsius
%	percent
λ	Wavelength